Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,deferredLongTermLiab,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,repurchaseOfStock,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,esgPopulated,tradeable,exchangeDataDelayedBy,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,trailingPE,epsTrailingTwelveMonths,epsForward,epsCurrentYear,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,priceHint,exchange,marketState,market,shortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Apr 29, 2021) 4","Short Ratio (Apr 29, 2021) 4","Short % of Float (Apr 29, 2021) 4","Short % of Shares Outstanding (Apr 29, 2021) 4","Shares Short (prior month Mar 30, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry,address2
t0,JAZZ,751245000,56891700,69651000,,139851000,,121832000,267430000,567392000,162119000,162119000,,-27376000,,,,18019000,607581000,445462000,40189000,-22268000,,121832000,121832000,2108046000,2694858000,2958781000,3797689000,4724000,83969000,6756470000,6000,147727000,1281726000,217635000,938398000,-178901000,289029000,2097533000,752093000,258454000,250140000,-178901000,249601000,3166896000,4500000,335000000,413976000,1853033000,115475000,77738000,739300000,50655000,737132000,-8347000,18276000,15261000,50407000,1039764000,-23784000,-641000,284997000,72971000,-22014000,-18245000,24224000,-2168000,2414803000,en-US,US,EQUITY,True,Delayed Quote,USD,False,False,0,1.699997,0.013049795,130.27 - 189.0,-57.03,-0.301746,130.27,189.0,1620158400,1635764340,1636113600,31.272514,4.22,17.79,14.49,0.1973992,130.61 - 133.42,131.71,0.0,0.0,9,8,finmb_6724933,NasdaqGS,Jazz Pharmaceuticals plc,USD,674050,651885,9.10766,65.154,154.51028,-22.540283,-0.14588208,167.38942,-35.41942,-0.2115989,7507997696,7.418212,2.0255089,15,America/New_York,EDT,-14400000,2,NMS,PRE,us_market,Jazz Pharmaceuticals plc,131.97,1630526402,0.2599945,131.58,133.42,130.61,696204,1.06,,,189.0,130.27,154.51,167.39,674.05k,651.88k,56.89M,,55.44M,2.72%,98.80%,5.26M,9.32,10.72%,9.24%,4.7M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",21.27%,31.97%,8.13%,15.69%,2.44B,43.63,13.60%,2.21B,1.06B,518.28M,4.22,,2.43B,42.75,2.25B,59.33,4.21,65.15,911.68M,675.69M,Value,4,Healthcare,1940,9,1,"Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP-150 for treatment of post-traumatic stress disorder. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc . The company was founded in 2003 and is headquartered in Dublin, Ireland.",Dublin,353 1 634 7800,5,1609372800,1619740800,5,Ireland,http://www.jazzpharma.com,86400,5,Waterloo Exchange,Biotechnology,Fifth Floor Waterloo Road
t-1,JAZZ,506391000,56891700,91699000,,144181000,,133414000,247172000,615360000,209414000,209414000,,-27573000,,,,10767000,665517000,456103000,50157000,-65233000,,133414000,133414000,2195051000,2633670000,2876156000,3659745000,5238000,48023000,6535901000,6000,152491000,1159894000,233860000,958303000,-133825000,281375000,1057769000,653745000,254916000,249157000,-133825000,257104000,2839568000,4500000,1075000000,396490000,1848516000,95396000,26945000,99075000,-40760000,73219000,-8347000,55878000,-14285000,65342000,315827000,-1117000,459000,186271000,71672000,-8676000,-33643000,64554000,-4115000,2185823000,en-US,US,EQUITY,True,Delayed Quote,USD,False,False,0,1.699997,0.013049795,130.27 - 189.0,-57.03,-0.301746,130.27,189.0,1620158400,1635764340,1636113600,31.272514,4.22,17.79,14.49,0.1973992,130.61 - 133.42,131.71,0.0,0.0,9,8,finmb_6724933,NasdaqGS,Jazz Pharmaceuticals plc,USD,674050,651885,9.10766,65.154,154.51028,-22.540283,-0.14588208,167.38942,-35.41942,-0.2115989,7507997696,7.418212,2.0255089,15,America/New_York,EDT,-14400000,2,NMS,PRE,us_market,Jazz Pharmaceuticals plc,131.97,1630526402,0.2599945,131.58,133.42,130.61,696204,1.06,,,189.0,130.27,154.51,167.39,674.05k,651.88k,56.89M,,55.44M,2.72%,98.80%,5.26M,9.32,10.72%,9.24%,4.7M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",21.27%,31.97%,8.13%,15.69%,2.44B,43.63,13.60%,2.21B,1.06B,518.28M,4.22,,2.43B,42.75,2.25B,59.33,4.21,65.15,911.68M,675.69M,Value,4,Healthcare,1940,9,1,"Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP-150 for treatment of post-traumatic stress disorder. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc . The company was founded in 2003 and is headquartered in Dublin, Ireland.",Dublin,353 1 634 7800,5,1609372800,1619740800,5,Ireland,http://www.jazzpharma.com,86400,5,Waterloo Exchange,Biotechnology,Fifth Floor Waterloo Road
t-2,JAZZ,198995000,56891700,78647000,,167517000,,148234000,207255000,558793000,206207000,206207000,,-26828000,,,,19283000,600888000,394681000,42095000,-38690000,,148234000,148234000,2241107000,2537989000,2914757000,3377201000,5802000,47269000,6291958000,6000,127258000,1026480000,287014000,937099000,-187274000,294758000,741942000,642133000,254810000,248142000,-187274000,258921000,2555573000,4500000,1175000000,361664000,1843685000,91404000,67063000,-266275000,14201000,-279644000,-31647000,-22656000,33136000,10088000,-44140000,-1097000,271000,257889000,71494000,-3035000,-8644000,17075000,-3369000,1913440000,en-US,US,EQUITY,True,Delayed Quote,USD,False,False,0,1.699997,0.013049795,130.27 - 189.0,-57.03,-0.301746,130.27,189.0,1620158400,1635764340,1636113600,31.272514,4.22,17.79,14.49,0.1973992,130.61 - 133.42,131.71,0.0,0.0,9,8,finmb_6724933,NasdaqGS,Jazz Pharmaceuticals plc,USD,674050,651885,9.10766,65.154,154.51028,-22.540283,-0.14588208,167.38942,-35.41942,-0.2115989,7507997696,7.418212,2.0255089,15,America/New_York,EDT,-14400000,2,NMS,PRE,us_market,Jazz Pharmaceuticals plc,131.97,1630526402,0.2599945,131.58,133.42,130.61,696204,1.06,,,189.0,130.27,154.51,167.39,674.05k,651.88k,56.89M,,55.44M,2.72%,98.80%,5.26M,9.32,10.72%,9.24%,4.7M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",21.27%,31.97%,8.13%,15.69%,2.44B,43.63,13.60%,2.21B,1.06B,518.28M,4.22,,2.43B,42.75,2.25B,59.33,4.21,65.15,911.68M,675.69M,Value,4,Healthcare,1940,9,1,"Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP-150 for treatment of post-traumatic stress disorder. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc . The company was founded in 2003 and is headquartered in Dublin, Ireland.",Dublin,353 1 634 7800,5,1609372800,1619740800,5,Ireland,http://www.jazzpharma.com,86400,5,Waterloo Exchange,Biotechnology,Fifth Floor Waterloo Road
t-3,JAZZ,-62342000,56891700,78922000,,169555000,,114801000,191406000,534428000,201126000,201126000,,-21735000,,,,54754000,562436000,361310000,28008000,-31571000,,114801000,114801000,2286126000,2499135000,2924696000,3141805000,6347000,69849000,6066501000,6000,112701000,878246000,300623000,918021000,-235582000,294070000,786082000,409960000,243395000,38686000,-235582000,261438000,2302346000,4500000,910000000,351920000,2069849000,92534000,50043000,-635475000,-15520000,-741165000,640147000,642534000,-1374000,10987000,84480000,-8600000,592000,182519000,67713000,-8591000,-34221000,22266000,-2690000,1892386000,en-US,US,EQUITY,True,Delayed Quote,USD,False,False,0,1.699997,0.013049795,130.27 - 189.0,-57.03,-0.301746,130.27,189.0,1620158400,1635764340,1636113600,31.272514,4.22,17.79,14.49,0.1973992,130.61 - 133.42,131.71,0.0,0.0,9,8,finmb_6724933,NasdaqGS,Jazz Pharmaceuticals plc,USD,674050,651885,9.10766,65.154,154.51028,-22.540283,-0.14588208,167.38942,-35.41942,-0.2115989,7507997696,7.418212,2.0255089,15,America/New_York,EDT,-14400000,2,NMS,PRE,us_market,Jazz Pharmaceuticals plc,131.97,1630526402,0.2599945,131.58,133.42,130.61,696204,1.06,,,189.0,130.27,154.51,167.39,674.05k,651.88k,56.89M,,55.44M,2.72%,98.80%,5.26M,9.32,10.72%,9.24%,4.7M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",21.27%,31.97%,8.13%,15.69%,2.44B,43.63,13.60%,2.21B,1.06B,518.28M,4.22,,2.43B,42.75,2.25B,59.33,4.21,65.15,911.68M,675.69M,Value,4,Healthcare,1940,9,1,"Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP-150 for treatment of post-traumatic stress disorder. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc . The company was founded in 2003 and is headquartered in Dublin, Ireland.",Dublin,353 1 634 7800,5,1609372800,1619740800,5,Ireland,http://www.jazzpharma.com,86400,5,Waterloo Exchange,Biotechnology,Fifth Floor Waterloo Road
